Cardiosense is a digital biomarker platform that provides multi-sensor devices and proprietary algorithms to detect early signs of diseases.
Cardiosense has raised $15.1M in total funding. The most recent round was Series A. The last funding was announced in December 2022.
Cardiosense's investors include Hatteras Venture Partners, Portal Innovations, OSF Ventures, Laerdal Million Lives Fund, UnityPoint Health Ventures.
Cardiosense is headquartered in Chicago, United States.
Cardiosense is a digital biomarker platform that provides multi-sensor devices and proprietary algorithms to detect early signs of diseases.
Cardiosense is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardiosense — Funding & Investors." VCBacked, December 8, 2022, https://www.vcbacked.co/company/cardiosense. Accessed September 30, 2026.
VCBacked. (2022). Cardiosense — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cardiosense
{{cite web |title=Cardiosense — Funding & Investors |url=https://www.vcbacked.co/company/cardiosense |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated